Abstract:Cellular senescence is characterized by stable cell-cycle arrest and a secretory program that modulates the tissue microenvironment<a href="/articles/s41586-020-2403-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2403-9#ref-CR2">2</a>. Physiologically, senescence serves as a tumour-suppressive mechanism that prevents the expansion of premalignant cells<a href="/articles/s41586-020-2403-9#ref-CR3">3</a>,<a href="/articles/s41586-020-2403-9#ref-CR4">4</a> and has a beneficial role in wound-healing responses<a href="/articles/s41586-020-2403-9#ref-CR5">5</a>,<a href="/articles/s41586-020-2403-9#ref-CR6">6</a>. Pathologically, the aberrant accumulation of senescent cells generates an inflammatory milieu that leads to chronic tissue damage and contributes to diseases such as liver and lung fibrosis, atherosclerosis, diabetes and osteoarthritis<a href="/articles/s41586-020-2403-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2403-9#ref-CR7">7</a>. Accordingly, eliminating senescent cells from damaged tissues in mice ameliorates the symptoms of these pathologies and even promotes longevity<a href="/articles/s41586-020-2403-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2403-9#ref-CR2">2</a>,<a href="#ref-CR8">8</a>,<a href="#ref-CR9">9</a>,<a href="/articles/s41586-020-2403-9#ref-CR10">10</a>. Here we test the therapeutic concept that chimeric antigen receptor (CAR) T cells that target senescent cells can be effective senolytic agents. We identify the urokinase-type plasminogen activator receptor (uPAR)<a href="/articles/s41586-020-2403-9#ref-CR11">11</a> as a cell-surface protein that is broadly induced during senescence and show that uPAR-specific CAR T cells efficiently ablate senescent cells in vitro and in vivo. CAR T cells that target uPAR extend the survival of mice with lung adenocarcinoma that are treated with a senescence-inducing combination of drugs, and restore tissue homeostasis in mice in which liver fibrosis is induced chemically or by diet. These results establish the therapeutic potential of senolytic CAR T cells for senescence-associated diseases.

Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

Senolytic CAR T cells reverse senescence-associated pathologies

Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction

Step Further Towards Targeted Senolytic Therapy:Therapeutic Potential of Upar-Car T Cells for Senescence-Related Diseases

In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism.

Step further towards targeted senolytic therapy: therapeutic potential of uPAR-CAR T cells for senescence-related diseases

In Situ Engineering of Mrna-Car T Cells Using Spleen-Targeted Ionizable Lipid Nanoparticles to Eliminate Cancer Cells

Synergically enhanced anti-tumor immunity of in vivo CAR by circRNA vaccine boosting

Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering

Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy

Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy

Enhancing CAR Macrophage Efferocytosis via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling

Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy

"All in one" lipid-polymer nanodelivery system for gene therapy of ischemic diseases

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

Lipid Nanoparticles Produce Chimeric Antigen Receptor T Cells with Interleukin-6 Knockdown in Vivo

Enhancing CAR‐NK Cells Against Solid Tumors Through Chemical and Genetic Fortification with DOTAP‐Functionalized Lipid Nanoparticles

Engineering Hierarchical Recognition-Mediated Senolytics for Reliable Regulation of Cellular Senescence and Anti-Atherosclerosis Therapy

Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair

Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System In Vivo to Treat Heart Disease